Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	33.03	35.49	40.46	62.88	21.23	14.95
Short-Term Investments	146.77	165.88	236.11	145.47	119.22	63.26
Cash & Cash Equivalents	179.8	201.37	276.56	208.36	140.45	78.21
Cash Growth	-30.22%	-27.19%	32.74%	48.35%	79.59%	-27.20%
Other Current Assets	5.82	5.58	9.16	3.3	4.36	2.93
Total Current Assets	185.61	206.95	285.72	211.65	144.81	81.13
Property, Plant & Equipment	8.02	8.69	13.17	6	6.75	8.1
Other Long-Term Assets	5.5	5.6	0.67	0.28	0.28	0.28
Total Long-Term Assets	13.52	14.29	13.85	6.28	7.03	8.38
Total Assets	199.13	221.24	299.57	217.93	151.84	89.51
Accounts Payable	5.06	8.25	2.48	2.03	2.36	0.82
Current Debt	4.44	3.01	2.57	1.2	1.04	0.9
Other Current Liabilities	6.66	6.48	5.95	4.99	3.04	4.28
Total Current Liabilities	16.16	17.74	11	8.21	6.44	6
Long-Term Debt	13.85	15.92	18.7	12.85	4.42	5.46
Total Long-Term Liabilities	13.85	15.92	18.7	12.85	4.42	5.46
Total Liabilities	30.01	33.67	29.7	21.06	10.86	11.47
Total Debt	18.29	18.93	21.26	14.04	5.46	6.36
Debt Growth	-11.74%	-10.96%	51.41%	157.03%	-14.14%	-
Retained Earnings	-372.42	-350.76	-248.89	-180.65	-126.02	-84.28
Comprehensive Income	-0.36	-0.13	-0.92	-0.29	-0.14	-0.2
Shareholders' Equity	169.12	187.57	269.87	196.88	140.98	78.05
Net Cash / Debt	161.51	182.44	255.3	194.31	134.98	71.84
Net Cash / Debt Growth	-31.84%	-28.54%	31.39%	43.95%	87.89%	-33.13%
Net Cash Per Share	2.22	2.51	3.79	3.68	3.07	3.76
Working Capital	169.45	189.21	274.73	203.44	138.37	75.13
Book Value Per Share	2.32	2.58	4.01	3.73	3.20	4.09

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).